Payment overview · 2025
General Payments
$331.29
5 reported records · 3 companies
Healthcare provider profile · identity verified
Lev Yagudayev, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine|Endocrinology, Diabetes & Metabolism · FRESH MEADOWS, NY · NPI 1881885432
Verified facts
What the public records show
CMS Open Payments records show Lev Yagudayev, M.D. received $331.29 in general payments during 2025 across 5 reported records.
GENZYME CORPORATION accounted for 45.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 3 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Jardiance by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $150.00 | 45.3% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $125.00 | 37.7% | 1 | 2025 |
| Organon LLC | Unresolved — no canonical attribution shown | $56.29 | 17.0% | 3 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $331.29 | 5 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| DUPIXENT Normalized: dupixent |
Biological | GENZYME CORPORATION | $150.00 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| VTAMA Normalized: vtama |
Drug | Organon LLC | $56.29 | 3 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 389 | 46 |
| Amlodipine Besylate | Amlodipine Besylate | 384 | 38 |
| Metoprolol Tartrate | Metoprolol Tartrate | 262 | 24 |
| Eliquis | Apixaban | 176 | 19 |
| Gabapentin | Gabapentin | 160 | 21 |
| Tamsulosin Hcl | Tamsulosin Hcl | 159 | 21 |
| Mirtazapine | Mirtazapine | 149 | 12 |
| Famotidine | Famotidine | 129 | 17 |
| Hydralazine Hcl | Hydralazine Hcl | 123 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 113 | 12 |
| Furosemide | Furosemide | 113 | 23 |
| Levetiracetam | Levetiracetam | 99 | 11 |
| Baclofen | Baclofen | 94 | suppressed |
| Simvastatin | Simvastatin | 91 | suppressed |
| Losartan Potassium | Losartan Potassium | 79 | 13 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 73 | 14 |
| Pantoprazole Sodium | Pantoprazole Sodium | 68 | 19 |
| Carvedilol | Carvedilol | 61 | suppressed |
| Latanoprost | Latanoprost | 60 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 59 | 17 |
| Finasteride | Finasteride | 56 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 55 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 55 | suppressed |
| Mupirocin | Mupirocin | 55 | 14 |
| Quetiapine Fumarate | Quetiapine Fumarate | 55 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 53 | 14 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 52 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 50 | suppressed |
| Lisinopril | Lisinopril | 49 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 47 | 12 |
| Levothyroxine Sodium | Levothyroxine Sodium | 45 | 12 |
| Metformin Hcl | Metformin Hcl | 45 | suppressed |
| Januvia | Sitagliptin Phosphate | 42 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 42 | suppressed |
| Risperidone | Risperidone | 42 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 41 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 41 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 40 | 12 |
| Sertraline Hcl | Sertraline Hcl | 40 | suppressed |
| Folic Acid | Folic Acid | 37 | suppressed |
| Admelog Solostar | Insulin Lispro | 35 | 12 |
| Ondansetron Hcl | Ondansetron Hcl | 34 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 34 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 32 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 30 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 30 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 30 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 29 | suppressed |
| Allopurinol | Allopurinol | 28 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 27 | suppressed |
| Memantine Hcl | Memantine Hcl | 27 | suppressed |
| Omeprazole | Omeprazole | 27 | 11 |
| Haloperidol | Haloperidol | 26 | suppressed |
| Nifedipine Er | Nifedipine | 26 | suppressed |
| Timolol Maleate | Timolol Maleate | 26 | suppressed |
| Gentamicin Sulfate | Gentamicin Sulfate | 24 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 24 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 24 | suppressed |
| Atenolol | Atenolol | 23 | suppressed |
| Spironolactone | Spironolactone | 23 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 22 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 22 | suppressed |
| Meropenem | Meropenem | 22 | suppressed |
| Synthroid | Levothyroxine Sodium | 22 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 21 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 21 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 21 | suppressed |
| Dorzolamide Hcl | Dorzolamide Hcl | 20 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 20 | suppressed |
| Jardiance | Empagliflozin | 20 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 20 | suppressed |
| Lumigan | Bimatoprost | 20 | suppressed |
| Novolog Flexpen | Insulin Aspart | 19 | suppressed |
| Olanzapine | Olanzapine | 19 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 18 | suppressed |
| Lactulose | Lactulose | 18 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 18 | suppressed |
| Daptomycin | Daptomycin | 17 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 17 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 17 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 16 | suppressed |
| Amantadine | Amantadine Hcl | 15 | suppressed |
| Nystatin | Nystatin | 15 | suppressed |
| Xarelto | Rivaroxaban | 15 | suppressed |
| Dextrose In Water | Dextrose 5 % In Water | 14 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 14 | suppressed |
| Lamotrigine | Lamotrigine | 14 | suppressed |
| Piperacillin-Tazobactam | Piperacillin Sodium/Tazobactam | 14 | suppressed |
| Prednisone | Prednisone | 14 | suppressed |
| Tradjenta | Linagliptin | 14 | suppressed |
| Novolin R Flexpen | Insulin Regular, Human | 13 | suppressed |
| Topiramate | Topiramate | 13 | suppressed |
| Biktarvy | Bictegrav/Emtricit/Tenofov Ala | 12 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 12 | suppressed |
| Methenamine Mandelate | Methenamine Mandelate | 11 | suppressed |
| Methocarbamol | Methocarbamol | 11 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 11 | suppressed |
| Rocklatan | Netarsudil Mesylat/Latanoprost | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $331.29 · 5 records | GENZYME CORPORATION | DUPIXENT, JARDIANCE, VTAMA | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Boehringer Ingelheim Pharmaceuticals, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error